A class action lawsuit has been filed against Corcept Therapeutics Incorporated alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The lawsuit claims defendants overstated the drug's approval likelihood while the FDA had raised significant concerns about the clinical evidence supporting the New Drug Application. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are encouraged to join the case.

The Gross Law Firm announces a securities class action lawsuit against Corcept Therapeutics (CORT) for allegedly making false and misleading statements regarding FDA interactions and expectations for relacorilant NDA approval. The lawsuit covers the period from October 31, 2024 to December 30, 2025, with a lead plaintiff deadline of April 21, 2026. Shareholders who purchased CORT shares during this period are encouraged to register for potential recovery.

Hagens Berman alerts Corcept Therapeutics (CORT) investors of an April 21, 2026 lead plaintiff deadline in a securities fraud class action. The lawsuit alleges Corcept concealed FDA warnings about insufficient clinical data for its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, causing CORT stock to plummet 50% from $70.20 to $34.80, erasing $2.5 billion in market value.

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corcept's stock plummeted 50.4% following the December 31, 2025 disclosure. Investors who purchased shares between October 31, 2024, and December 30, 2025, are eligible to participate in the lawsuit.

Levi & Korsinsky filed a class action securities lawsuit against Corcept Therapeutics for alleged fraud between October 31, 2024 and December 30, 2025. The complaint alleges that defendants made false statements about FDA interactions regarding relacorilant's NDA approval prospects, when the FDA had actually expressed concerns about the drug's effectiveness assessment program and the GRACE study design. Investors who suffered losses during this period can request lead plaintiff status by April 21, 2026.

Hagens Berman announced a securities class action lawsuit against Corcept Therapeutics (CORT) for allegedly concealing FDA warnings about its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, citing insufficient evidence of effectiveness, causing CORT's stock to crash 50% from $70.20 to $34.80 in a single day. Investors with losses between October 31, 2024, and December 30, 2025, have until April 21, 2026, to become lead plaintiffs.

A class action lawsuit has been filed against Corcept Therapeutics Incorporated for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements about the strength of clinical trials supporting relacorilant and overstated confidence in its regulatory approval prospects, while failing to disclose that the FDA had raised concerns about the adequacy of clinical evidence supporting the NDA.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Corcept Therapeutics, Lakeland Industries, and Navan, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding clinical trials, business operations, and sales/marketing expenses respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in April 2026.

A class action lawsuit has been filed against Corcept Therapeutics Incorporated for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements about the strength of clinical trials supporting relacorilant and overstated confidence in its regulatory approval prospects, while failing to disclose that the FDA had raised concerns about the adequacy of clinical evidence. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 21, 2026.

Rosen Law Firm is soliciting investors who purchased Corcept Therapeutics common stock between October 31, 2024 and December 30, 2025 to join a securities class action lawsuit. The lawsuit alleges that Corcept made misleading statements about clinical trial support for its relacorilant drug and FDA approval prospects, while the FDA had raised concerns about the adequacy of clinical evidence. The lead plaintiff deadline is April 21, 2026.

A class action lawsuit has been filed against Corcept Therapeutics for allegedly making false and misleading statements about its relacorilant drug's clinical trial strength and regulatory approval prospects. The lawsuit covers investors who purchased Corcept securities between October 31, 2024 and December 30, 2025. The FDA had raised concerns about the adequacy of clinical evidence, contrary to the company's claims of no impediments to approval.

The Schall Law Firm is seeking investors who purchased Corcept Therapeutics (NASDAQ: CORT) securities between October 31, 2024 and December 30, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its product candidate relacorilant, claiming it was 'approaching approval' while knowing the FDA considered the clinical data inadequate for approval.